Methotrexate |
Rheumatrex; Trexall |
Clinical Trial: Assessment of Rituximab''s Immunomodulatory Synovial Effects (The ARISE Study)
This study is currently recruiting patients.
Verified by University of California, San Diego September 2005
|
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Rheumatoid Arthritis active disease despite concomitant methotrexate | Drug: arthroscopic biopsy | Phase II |
MedlinePlus related topics: Rheumatoid Arthritis
Study Type: Interventional
Study Design: Diagnostic, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study
Official Title: Assessment of the Immunomodulatory Effects of Rituximab in Seropositive Rheumatoid Arthritis Using Arthroscopic Synovial Biopsies
Eligibility
Inclusion Criteria:
- Active rheumatoid arthritis use of concomitant methotrexate
Exclusion Criteria:
- Use of DMARDs/biologics other than methotrexate serious medical conditions that would preclude the use of the treating agent
Location and Contact Information
California
UCSD CIT, La Jolla, California, 92093, United States; Recruiting
Arthur Kavanaugh, MD, Principal Investigator, UCSD CIT
More Information
Last Updated: September 6, 2005
Record first received: September 2, 2005
ClinicalTrials.gov Identifier: NCT00147966
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
Resources
- Methotrexate (Drug Digest)
- Methotrexate (Cleveland Clinic)

Not Signed In -


